Expanding Medicare coverage of costly weight loss drugs could come at a steep cost for the federal government. Allowing Medicare to cover obesity medications would increase federal spending by about ...

More than half of independent pharmacies are considering not stocking the first 10 drugs that were subject to Medicare price ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

Total direct federal costs of covering AOMs would increase from $1.6 billion in 2026 to $7.1 billion in 2034, CBO finds.

One of the biggest changes takes effect in 2025. Part D drug plans must cap out-of-pocket spending on covered drugs at $2,000 ...

Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Help with the sometimes-complicated process of comparing Medicare plans for 2025 is available in Oregon for no charge.

Medicare covers Wegovy as a treatment to reduce the risk of serious cardiovascular events in people who have overweight or obesity. It does not cover Wegovy for weight loss.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Good afternoon ...